Jones Trading Upgrades BioLine Rx to Buy, Announces $12 Price Target
Benzinga Newsdesk 1 year ago
NewsUpgradesPrice TargetAnalyst Ratings
Jones Trading analyst Justin Walsh upgrades BioLine Rx (NASDAQ:BLRX) from Hold to Buy and announces $12 price target.
Jones Trading analyst Justin Walsh upgrades BioLine Rx (NASDAQ:BLRX) from Hold to Buy and announces $12 price target.